Drug Trial Radar · NCT07318714
A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Apr 3, 2026
Primary completion
Feb 28, 2030
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for adults who have difficulty moving a few months after a stroke. In this study, ASP2246 will be given to people for the first time. This is known as a "first in human" study. The main aims of the study are to check the safety of ASP2246, how well people tolerate it, and to find suitable doses of ASP2246 to use later in this study and in future studies. This study has 2 parts. In Part 1, people will have brain surgery. During the surgery, different small groups of people will receive a lower to a higher dose of ASP2246. Each dose will be given slowly through a special tube to the damaged part of the brain (intracerebral parenchymal infusion). Any medical problems will be recorded at each dose. This is done to find suitable doses to use in Part 2 of the study. In Part 2, other different groups of people will undergo the same type of brain surgery. Some people will receive a higher dose of ASP2246, and some people will receive a lower dose of ASP2246. These are the doses from Part 1. Also, another group of people won't be given ASP2246 during brain surgery. This is known as a sham procedure. This is done so neither the people taking part in Part 2, nor the study doctors (apart from the surgeons) know who will be given ASP2246. After brain surgery, people will be observed for about 2 weeks. For people in Part 1, this will take place in the hospital. For people in Part 2, the observation in hospital may be longer or shorter, depending on the results from Part 1. People in both Parts 1 and 2 will have physical therapy for 12 weeks after surgery and continue to have safety checks for about 1 year after their brain surgery.
Conditions
- Chronic Ischemic Stroke
Interventions
ASP2246Drug
Intracerebral parenchymal infusion via SmartFlow Neuro cannula.
Brain surgeryProcedure
Stereotactic brain surgery
Sham surgeryProcedure
Sham surgery without the dura incised.
Rehabilitation therapyOther
Rehabilitation 3 days per week for up to 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose-Limiting Toxicity (DLT)Time frame: Up to 2 Weeks
- Number of participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 52 Weeks
- Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 52 Weeks
- Number of participants with an Adverse Event of Special Interest (AESI)Time frame: Up to 52 Weeks
- Number of Participants with Suicidal Ideation and/or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 52 Weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Kyoto University Hospital
Kyoto, Japan · Recruiting
Tokushima University Hospital
Tokushima, Japan · Recruiting
Tohoku University Hospital
Sendai, Miyagi, Japan · Recruiting
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan · Recruiting
Toyama University Hospital
Toyama, Toyama, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.